RxDoctor Payments DataLook up a doctor →

Amy Tobin, DO

Endocrinology, Diabetes & Metabolism · Sterling Heights, MINPI 1093743007

Payments from drug & device makers

$36,529in general payments, 2019–2025

Across 1,130 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Novo Nordisk$4K
  • Amgen$3K
  • Abbott$3K
  • Cequr Corporation$2K
  • Lilly USA, LLC$2K
  • plus $16K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)121$6,677
Novo Nordisk168$3,627
Amgen(2 entities)82$2,902
Abbott34$2,562
Cequr Corporation5$2,443
Lilly USA, LLC103$2,120
AstraZeneca(2 entities)49$1,912
Dexcom, Inc.28$1,439
Mannkind Corporation54$1,146
Sanofi-aventis U.S. LLC48$1,053
Tandem Diabetes Care, Inc.6$833
Bayer31$823
Corcept Therapeutics35$740
AbbVie27$609
Xeris Pharmaceuticals, Inc.25$545
Ascendis Pharma Endocrinology Inc7$432
Boehringer Ingelheim21$391
Radius Health, Inc.18$371
BD15$335
Amneal Pharmaceuticals LLC17$315
Amarin Pharma, Inc.21$307
Merck21$255
Madrigal Pharmaceuticals5$252
Antares Pharma, Inc.7$245
Lifescan, Inc.15$243
Kyowa Kirin, Inc.6$233
Senseonics, Incorporated4$230
Vistapharm, Inc.6$225
Sequel Med Tech, LLC5$218
Insulet Corporation8$209
Nevro Corp.4$203
Ultragenyx Pharmaceutical Inc.9$187
Johnson & Johnson19$178
Esperion Therapeutics, Inc.3$161
Valeritas, Inc.3$153
Recordati_rare_diseases_inc.7$150
Alvogen Inc7$147
Ascensia Diabetes Care US Inc.8$146
Clarus Therapeutics Inc.2$137
Ipsen Biopharmaceuticals, Inc6$121
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$108
Amphastar Pharmaceuticals, Inc.5$90
Shire North American Group Inc6$88
Averitas Pharma Inc.3$85
Pfizer4$84
Neurocrine Biosciences, Inc.3$76
Amryt Pharma Holdings Ltd5$75
Embecta Corp.4$72
IBSA Pharma Inc.4$66
Takeda Pharmaceuticals U.S.A., Inc.2$62
Vivus LLC3$57
Chiesi USA, Inc.3$51
Medline Industries LP1$45
BETA Bionics, Inc.3$39
Zealand Pharma US, Inc.2$39
Tolmar, Inc.2$32
GRT US Holding, Inc.2$28
Eisai Inc.2$27
Bigfoot Biomedical Inc1$23
Verity Pharmaceuticals Inc.1$19

How this compares

$36,529 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024
$60,768
Medicare patients
145
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Sterling Heights

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →